Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy - PubMed
7 hours ago
- #metabolic rewiring
- #lipidomics
- #prostate cancer
- Lipidomic profiling in metastatic prostate cancer (PCa) reveals tumor metabolic changes influenced by androgen receptor (AR) signaling.
- Plasma lipidomics in metastatic castration-resistant PCa (mCRPC) patients shows distinct signatures compared to cancer-free subjects, including increased monounsaturated lipids and altered phospholipid/sphingolipid composition.
- Enzalutamide (Enza) treatment in mCRPC patients reduces total lipid levels, decreases phospholipids and ceramides, while increasing sphingomyelins.
- Specific sphingolipid changes post-Enza treatment correlate with survival outcomes, indicating prognostic relevance.
- Plasma lipidomics serves as a non-invasive tool for monitoring disease activity and treatment response in mCRPC, with potential for lipid-based biomarkers.